Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb Company (BMY) Guggenheim Securities Inaugural Healthcare Innovation Conference (Transcript)
Bristol-Myers Squibb Company (NYSE:BMY ) Guggenheim Securities Inaugural Healthcare Innovation Conference November 11, 2024 10:00 AM ET Company Participants Samit Hirawat - EVP, Chief Medical Officer, Global Drug Development Robert Plenge - EVP, Chief Research Officer Conference Call Participants Seamus Fernandez - Guggenheim Seamus Fernandez Okay. So, in the interest of staying on time here, really pleased to have Bristol Myers Squibb joining us.
Bristol Myers Stock Trading Near 52-Week High: Time to Buy or Sell?
BMY has been having a good run for the past three months. The stock recently touched a 52-week high.
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve's interest rate cuts in September.
What's Next For BMY Stock After An Upbeat Q3?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q3 results, with revenues and earnings exceeding the street estimates. It reported revenue of $11.9 billion and adjusted earnings of $1.80 per share, compared to the consensus estimates of $11.3 billion and $1.49, respectively.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Merck vs. Bristol-Myers: Analyst Views Differ After Q3 Earnings
With many of the Magnificent 7 stocks reporting earnings the week of October 28, investors' attention was on technology stocks. But that means you may have overlooked two biopharmaceutical companies that delivered solid earnings reports.
5 Must Own High-Yield Dividend Stocks If Kamala Harris Wins
24/7 Wall St. Insights The seemingly endless political season is almost over.
Stock Market Rally Is 2 Years Old: 3 Passive Income Favorites Are November Bargains
24/7 Wall St. Insights The long AI-driven rally has many tech stocks overvalued.
Bristol-Myers Tops Q3 Earnings and Sales Estimates, Ups 2024 EPS View
BMY posts impressive third-quarter results, with both earnings and sales beating the respective estimates. The company also raises its annual earnings guidance.
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Bristol-Myers Squibb Company (NYSE:BMY ) Q3 2024 Results Conference Call October 31, 2024 8:00 AM ET Company Participants Chuck Triano - Senior Vice President, Investor Relations Chris Boerner - Board Chair & Chief Executive Officer David Elkins - Chief Financial Officer Adam Lenkowsky - Chief Commercialization Officer Samit Hirawat - Chief Medical Officer & Head of Global Drug Development Conference Call Participants Evan Seigerman - BMO Capital Markets Chris Shibutani - Goldman Sachs Chris Schott - JPMorgan Luisa Hector - Berenberg Geoff Meacham - Citibank Carter Gould - Barclays Trung Huynh - UBS Steve Scala - Cowen Courtney Breen - Bernstein Seamus Fernandez - Guggenheim Securities Matt Phipps - William Blair David Risinger - Leerink Partners Akash Tewari - Jefferies James Shin - Deutsche Bank Olivia Brayer - Cantor Sean McCutchen - Raymond James Srikripa Devarakonda - Truist Securities Operator Good day, and welcome to the Bristol-Myers Squibb Third Quarter 2024 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
Compared to Estimates, Bristol Myers (BMY) Q3 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Bristol Myers Squibb (BMY) Tops Q3 Earnings and Revenue Estimates
Bristol Myers Squibb (BMY) came out with quarterly earnings of $1.80 per share, beating the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $2 per share a year ago.
